YD Bio Limited Ordinary Shares EBIT

As of the most recent data (June 2025), YDES shows a EBIT of $-3M. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

The Healthcare sector average EBIT is about $22B. YD Bio Limited Ordinary Shares is at $-3M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how YDES stacks up against individual peers as well.

Tracking YDES's ebit over time shows whether YD Bio Limited Ordinary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $-3M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has YD Bio Limited Ordinary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-3M) with ownership activity and broader fundamentals.

The Healthcare average EBIT is about $22B, while YDES is at $-3M. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.